FOXO4-DRI

Idiopathic Pulmonary Fibrosis

Amor et al. (2020) demonstrated that senolytic CAR-T cells targeting senescent cells could reverse fibrosis in murine models, providing complementary evidence that senescent cell clearance — the mechanism employed by FOXO4-DRI — can resolve fibrotic disease. FOXO4-DRI is being investigated as a pharmacological senolytic approach for fibrotic conditions where senescent cell accumulation drives pathology.

Targeted Apoptosis and Tissue Homeostasis Restoration

The foundational study by Baar et al. (2017) demonstrated that FOXO4-DRI selectively induced apoptosis in senescent human fibroblasts in vitro while sparing non-senescent cells in the same cultures. In fast-aging (XpdTTD/TTD) mice, FOXO4-DRI treatment restored fitness, fur density, and renal function. In naturally aged wild-type mice, the peptide counteracted age-related loss of condition and improved multiple health parameters. Critically, the peptide cleared senescent cells without apparent toxicity to normal tissues, confirming the senescence-specificity of the FOXO4-p53 targeting approach. Published in Cell 169(1):132-147.e16.

Chemotherapy-Induced Senescence

In the same study, Baar et al. (2017) showed that FOXO4-DRI was effective against chemotherapy-induced senescence. Doxorubicin treatment in mice induced widespread cellular senescence with associated liver toxicity. Subsequent FOXO4-DRI administration cleared the chemotherapy-induced senescent cells and ameliorated the associated tissue damage, suggesting potential utility in mitigating the long-term side effects of cancer treatment.

Senolytic Specificity Mechanism

Baar et al. (2017) provided molecular evidence for the selectivity mechanism: FOXO4 is specifically enriched in senescent cells and co-localizes with p53 in PML nuclear bodies. Non-senescent cells lack this FOXO4-p53 interaction and therefore do not undergo apoptosis upon FOXO4-DRI exposure. The study used fluorescence microscopy, co-immunoprecipitation, and senescence markers (SA-beta-galactosidase, p21, p16) to confirm that apoptosis was restricted to senescent cell populations.

Ongoing & Future Research

• Development of next-generation FOXO4-DRI variants with improved pharmacokinetic properties and reduced manufacturing cost (D-amino acid peptide synthesis is expensive)
• Investigation of FOXO4-DRI in organ-specific models of aging including brain aging, osteoarthritis, and atherosclerosis
• Research into biomarkers for monitoring senescent cell clearance and treatment response
• Combination studies with other senolytics and geroprotectors to optimize senolytic regimens
• Exploration of intermittent dosing strategies (hit-and-run senolytic approach) to minimize off-target effects
• De Keizer laboratory (University Medical Center Utrecht) continuing development of FOXO4-DRI-based senolytic therapies for clinical translation
• FOXO4-DRI analogs with cell-type-specific targeting moieties for tissue-selective senolysis

Senolytic Mechanisms (Deep Dive)

p53/p21/FOXO4 pathway in senescence maintenance:

• Cellular senescence is initiated by DNA damage, oncogene activation, or other stresses that activate p53, which transcriptionally induces p21 (CDKN1A), a cyclin-dependent kinase inhibitor that enforces cell-cycle arrest at G1 Campisi (2013) — Annu Rev Physiol
• p21 inhibits CDK2/cyclin E and CDK4/cyclin D complexes, preventing Rb phosphorylation and maintaining the senescence-associated growth arrest
• In established senescence, p16INK4a (CDKN2A) provides a secondary, p53-independent reinforcement of cell-cycle arrest through direct CDK4/6 inhibition
• FOXO4 is specifically upregulated in senescent cells and physically interacts with p53 in PML nuclear bodies, creating a spatial compartmentalization that prevents p53 from engaging its mitochondrial apoptotic targets

PML nuclear bodies as senescence hubs:

• PML bodies are nuclear substructures that concentrate regulatory proteins including p53, FOXO4, DAXX, and SUMO-modified proteins
• In senescent cells, FOXO4 and p53 co-localize in PML bodies at significantly higher rates than in proliferating cells
• This co-localization effectively "traps" p53, preventing it from initiating the intrinsic apoptosis cascade
• FOXO4-DRI disrupts this interaction, allowing p53 to exit PML bodies and translocate to mitochondria

Intrinsic apoptosis execution:

• Released p53 interacts with mitochondrial Bax/Bak to induce mitochondrial outer membrane permeabilization (MOMP)
• MOMP releases cytochrome c into the cytoplasm, activating the apoptosome (Apaf-1/caspase-9 complex)
• Downstream effector caspases (caspase-3, caspase-7) execute the apoptotic program
• Non-senescent cells, lacking the FOXO4-p53 interaction dependency, do not undergo this cascade upon FOXO4-DRI exposure

Comparison with other senolytic mechanisms:

• Dasatinib+Quercetin: Targets multiple SCAPs (BCL-2/BCL-xL, PI3K/AKT, p21, serpins); broader mechanism but less selectivity for senescent cells
• Navitoclax (ABT-263): Direct BCL-2/BCL-xL BH3 mimetic; potent but causes on-target thrombocytopenia due to platelet BCL-xL dependence
• UBX0101: MDM2-p53 interaction inhibitor; targets different p53-regulatory axis but failed Phase 2 clinical trial for osteoarthritis
• FOXO4-DRI: Among the most selective senolytics characterized, exploiting a dependency unique to the senescent state